Pharvaris N.V.

Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with unmet needs, specifically angioedema and other bradykinin-mediated diseases. Its lead product candidate is deucrictibant, a small molecule bradykinin B2-receptor antagonist designed to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). Deucrictibant is being developed in both extended-release tablet and immediate-release capsule formulations, and is currently in phase 3 clinical trials for the treatment and prophylaxis of HAE attacks.

Pharvaris N.V. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PHVS. Its shares are traded in US dollars (USD), reflecting its primary listing on a US exchange despite being headquartered in Switzerland. The company's stock is accessible to investors through major US brokerages and is part of the NasdaqGS, which typically includes larger and more established companies.

Pharvaris operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for rare diseases, particularly those involving bradykinin-mediated angioedema. The company's work involves advanced drug development, including small molecule antagonists, and it is currently in late-stage clinical trials, which is characteristic of many biotech firms aiming to bring new treatments to market.

Pharvaris N.V. is headquartered in Zug, Switzerland, and was incorporated in 2015. The company serves a global market, focusing on rare diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). While its primary listing is in the US, its therapeutic focus addresses unmet medical needs worldwide, and its clinical trials are likely conducted across multiple countries to support regulatory approvals in various regions.

Pharvaris is a late-stage biopharmaceutical company that generates revenue primarily through the development and eventual commercialization of its product candidates. Currently, its main focus is on deucrictibant, a small molecule bradykinin B2-receptor antagonist in phase 3 trials for hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency. The company aims to bring this therapy to market, after which it would generate revenue from sales of the drug. As a development-stage company, Pharvaris likely does not yet have significant product revenue and may rely on funding from investors, partnerships, or grants to support its operations and clinical trials.